Colorectal Cancer Recurrent Clinical Trial
Official title:
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer：One-arm Exploratory Clinical Trial
The efficacy and safety of the use of Camrelizumab combined with Apatinib
To evaluate the clinical efficacy and safety of Camrelizumab combined with Apatinib in the
treatment of patients with advanced gastric cancer and colorectal cancer.
The 62 patients were enrolled in a 2-week regimen with 200mg Camrelizumab given intravenously
every two weeks and 250mg apatinib mesylate every 4 weeks for a treatment cycle until
progressive or intolerable，then the objective remission rate(ORR) was calculated.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06229340 -
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
|
Phase 2 | |
| Recruiting |
NCT06314971 -
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
|
||
| Recruiting |
NCT06314958 -
Stage II/III Colorectal Cancer Recurrence
|
||
| Completed |
NCT02390947 -
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
|
Phase 3 | |
| Completed |
NCT04368507 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01762293 -
A Study of Famitinib in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT06271980 -
Early-Onset Colorectal Cancer Recurrence
|